Back to School: How biopharma can reboot drug development. Access exclusive analysis here
LGND dropped $5.405 (40%) to $8.175 on 29 million shares on Tuesday after
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury